SCHEMBL6548975

SCHEMBL6548975

COC(=O)c1ccc(-c2ccc3cc4c(cc3c2)C(c2cccc(C)c2)=CC(=O)C4(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RARA P10276 5/20 0.43
RARB P10826 5/20 0.43
RARG P13631 5/20 0.43
PLAU P00749 7/20 0.41
EGFR P00533 1/20 0.40
PLAT P00750 2/20 0.40
PLG P00747 1/20 0.40
CYP19A1 P11511 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
MAPK14 Q16539 1/20 0.39
PTPRC P08575 1/20 0.39
PTPRF P10586 1/20 0.39
PTPN1 P18031 1/20 0.39
CDC25B P30305 1/20 0.39
HSD17B2 P37059 1/20 0.38
PGR P06401 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SETD7 Q8WTS6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6908997 0.89 RARA (0.54) RARARARBRARGPGR
SCHEMBL6907265 0.83 RARB (0.64) RARARARBRARGPLAUEGFR
SCHEMBL31298127 0.75 EGFR (0.60) PLAUEGFRMAPK14PTPN1HSD17B2
SCHEMBL6138470 0.75 EGFR (0.60) PLAUEGFRMAPK14PTPN1HSD17B2
SCHEMBL8437231 0.70 RARB (0.66) RARARARBRARGPLAUCYP11B1
SCHEMBL8438543 0.69 RARB (0.54) RARARARBRARGPLAUEGFR
SCHEMBL8438952 0.69 RARB (0.56) RARARARBRARGPLAUEGFR
SCHEMBL8709650 0.68 CYP11B2 (0.58) RARARARBRARGCYP19A1CYP11B1
SCHEMBL28189889 0.67 EGFR (0.68) PLAUEGFRPLATPLGCYP19A1
SCHEMBL8709424 0.66 RARB (0.63) RARARARBRARGHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040122080-A1 Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer BRISTOL-MYERS SQUIBB COMPANY 2004-06-24 US disclosed
EP-1383491-A2 SYNERGISTIC COMBINATIONS OF RETINOID RECEPTOR LIGANDS AND SELECTED CYTOTOXIC AGENTS FOR TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2004-01-28 EP disclosed
WO-2002078620-A2 SYNERGISTIC COMBINATIONS OF RETINOID RECEPTOR LIGANDS AND SELECTED CYTOTOXIC AGENTS FOR TREATMENT OF CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122080-A1 Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer RARA, RARG, RARB RARA 1/4885RARB 3/4885RARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.